Screening method of L-threonine efflux protein and application of L-threonine efflux protein

Through a high-throughput screening method based on the whole genome of Corynebacterium glutamicum, specific L-threonine efflux protein was screened out, solving the problem of homoserine loss caused by nonspecificity of efflux protein in the prior art, and improving L- Threonine yield and production efficiency.

CN119061043APending Publication Date: 2024-12-03TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310643079.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-01
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The specificity of the existing L-threonine efflux protein is insufficient, resulting in homoserine efflux, which increases production costs and limits the increase in L-threonine production.

Method used

Using a high-throughput screening method based on the whole genome single gene overexpression library of Corynebacterium glutamicum, proteins that can specifically efflux L-threonine were screened out, and control plasmids and overexpression were constructed without cloning any gene sequences in the middle. Membrane transporter strains are subjected to primary screening and re-screening to ensure the function and specificity of the protein.

Benefits of technology

It has achieved rapid and effective screening of specific efflux proteins that can increase L-threonine production, reduced efflux of homoserine, and increased the extracellular concentration and yield of L-threonine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention discloses a screening method of threonine efflux protein and application of the threonine efflux protein. According to the high-throughput screening method of the functional gene based on the corynebacterium glutamicum whole genome single gene overexpression library, the L-threonine efflux protein capable of accelerating the transfer of excessive L-threonine to the extracellular is rapidly screened, so that the yield of the L-threonine of the strain is increased. According to overexpression of the six kinds of L-threonine efflux proteins in the screened corynebacterium glutamicum, compared with a control strain, the intracellular threonine concentrations of the six membrane protein overexpression strains at all time points are obviously lower than that of the control strain, and the extracellular threonine concentrations of the six membrane protein overexpression strains are obviously higher than that of the control strain, so that L-threonine can be efflux from the six screened membrane proteins. In addition, the excreted proteins Cgl2078, Cgl2344 and Cgl2656 cannot be used for excreting homoserine, so that the L-threonine can be more favorably produced and applied.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of genetic engineering, and specifically relates to a method for screening an L-threonine efflux protein and application of the L-threonine efflux protein. Background Art

[0002] L-threonine is one of the major amino acid varieties and one of the essential amino acids for growth. It is widely used in feed, food additives and preparation of pharmaceutical auxiliary materials. It is currently mainly produced by microbial fermentation. The main fermentation strains include Escherichia coli, Corynebacterium, Serratia, etc. Due to the physiological superiority of Corynebacterium, it has gradually become the main industrial fermentation strain.

[0003] With the increasing demand for L-threonine, researchers have continuously constructed engineered strains with high L-threonine production. For example, Kwang Ho Lee (Kwang Ho Lee et al., Systems metabolic engineering of Escherichiacoli for L-threonine production, Mol Syst Biol. 2007; 3: 149) used systems metabolic engineering strategies to remove product feedback inhibition by mutating the genes thrA and lysC encoding aspartate kinases I and III, removing by-products glycine and isoleucine by knocking out tdh and weakening ilvA, and providing more precursors for L-threonine synthesis by inactivating the competitive pathway genes metA and lysA. The final TH28C (pBRThrABCR3) strain obtained can produce 82.4 g / L of acid in 50 hours of fermentation, with a sugar-acid conversion rate of 39.3%.

[0004] Due to the limited ability of the current strain to excrete L-threonine, the intracellular L-threonine concentration is too high, which limits the further increase of the yield of high-yield bacteria. To address this problem, researchers have studied and reported proteins that can excrete L-threonine, such as Cgl0605 (Microb Cell Fact. 2020 May 29; 19 (1): 115.) and Cgl2622 (J Bacteriol. 2001 Sep; 183 (18): 5317-24.), which are L-threonine efflux proteins that have been reported in the literature. By overexpressing these efflux proteins, the yield of L-threonine can be increased. However, the L-threonine efflux proteins reported so far are not specific for threonine efflux, but also for homoserine. As a synthetic precursor of L-threonine, the efflux of homoserine obviously causes the loss of precursor for the synthesis of L-threonine. At the same time, the effluxed homoserine as a by-product at the end of fermentation also increases the cost of separation and extraction. Therefore, there is an urgent need to explore new specific L-threonine efflux proteins in this field. Summary of the invention

[0005] To overcome the problems in the prior art, the present invention first constructs a high-throughput screening method for functional genes based on a single gene overexpression library of the whole genome of Corynebacterium glutamicum, which is used for high-throughput rapid screening of L-threonine efflux proteins that can accelerate the transport of excess L-threonine to the extracellular space, thereby increasing the L-threonine yield of the strain. The present invention is completed on this basis.

[0006] The specific technical solutions of the present invention are as follows:

[0007] In a first aspect, a method for screening a microbial L-threonine efflux protein is provided, which specifically comprises the following steps:

[0008] 1) Construct a membrane transporter gene overexpression strain library based on the whole genome of microorganisms, and at the same time construct a control plasmid strain without any gene sequence cloned in the middle;

[0009] 2) At the same time, the effects of overexpression of membrane transporters on cell growth were compared under the conditions of culture with or without Thr-Thr dipeptide, and preliminary screening of L-threonine efflux proteins was performed;

[0010] 3) Cultivating the membrane transporter overexpressing strain obtained in the initial screening of step 2) under Thr-Thr dipeptide culture conditions, detecting L-threonine efflux by liquid chromatography, and performing rescreening by comparing with the control plasmid strain.

[0011] Preferably, the microorganism is a microorganism of the genus Corynebacterium; further preferably, the microorganism of the genus Corynebacterium is Corynebacterium glutamicum.

[0012] Preferably, the step 2) is specifically to transfer the seed solution of the membrane transporter gene overexpression strain of the whole genome of the microorganism constructed in step 1) and the control plasmid strain to a medium containing a final concentration of 6 mM Thr-Thr dipeptide and a medium without Thr-Thr dipeptide, respectively, and culture them using a MicroScreen fully automatic microbial growth curve analyzer, and automatically measure the OD 600 The cell growth OD was measured every 1 h. 600 Calculate the OD of the overexpression strain at every 1-hour interval under the culture condition of adding Thr-Thr dipeptide during the exponential growth period for 5 consecutive hours. 600 OD of the control plasmid strain 600 The ratio and the average of the ratios at these five time points; the OD of the overexpression strain at each 1-hour interval under the culture condition without adding dipeptide 600 OD of the control plasmid strain 600ratio and the average of the ratios at these five time points; then calculate the difference between the average of the five ratios under the culture condition with the addition of dipeptide and the average of the five ratios under the condition without the addition of dipeptide. If the difference is ≥40%, it indicates that the overexpression of the membrane transporter is specifically conducive to the growth under the Thr-Thr dipeptide culture condition and is a possible L-threonine efflux protein.

[0013] Further preferably, in step 2), the culture system is a 48-well plate, containing 400 μL of liquid, and the culture medium is a CGXII liquid culture medium containing 0.04 mM IPTG and 25 μg / mL kanamycin, and cultured at 30°C, 800 rpm for 18 h. The components of the CGXII liquid culture medium are (g / L): (NH4)2SO4, 20 g / L; urea, 5 g / L; KH2PO4, 1 g / L; K2HPO4·3H2O, 1.3 g / L; MOPS, 42 g / L; CaCl2, 0.01 g / L; FeSO4·7H2O, 0.01g / L; MnSO4·H2O, 0.01g / L; ZnSO4·7H2O, 0.001g / L; CuSO4, 0.0002g / L; NiCl·6H2O, 0.00002g / L; MgSO4·7H2O, 0.25g / L; Protocatechuic acid, 0.03g / L; Vitamin B1, 0.0001g / L; Biotin, 0.0002g / L; Glucose, 40g / L; H2SO4 is adjusted to pH 7.1-7.2.

[0014] Preferably, the step 3) is specifically to screen the strains overexpressing the membrane transporter protein obtained in the initial screening in step 2) and the strains containing the control plasmid by detecting the concentration of L-threonine using a liquid chromatograph (Tsushima, Japan); and to culture and measure the OD using a MicroScreen fully automatic microbial growth curve analyzer. 600 In the medium containing Thr-Thr dipeptide, the samples were cultured at 30℃ for 1 hour and then the rescreening evaluation standard was calculated by calculating the unit OD 600 The L-threonine efflux rate of the strain is L-threonine concentration / initial OD 600 (g / L / OD 600 ), the L-threonine efflux rate was more than 20% higher than that of the control.

[0015] Further preferably, in step 3), the culture system is a 48-well plate, filled with 400 μL of liquid, 800 rpm, and cultured at 30°C for 8 hours, then the bacterial liquid is inoculated into TSB liquid culture medium containing 0.04 mM IPTG and 25 μg / mL kanamycin. The culture system is a 48-well plate, filled with 400 μL of liquid, 800 rpm, and cultured at 30°C for 8 hours. The 48-well plate is centrifuged and the supernatant is discarded. 400 μL of CGXII fine-tuning culture medium with a concentration of 6 mM Thr-Thr dipeptide is added and mixed by pipetting. The culture medium contains 0.4 mM IPTG and 25 μg / mL kanamycin. After culturing at 800 rpm and 30°C for 1 hour, a sample is taken to detect the OD 600 The components of the CGXII liquid culture medium are (g / L): (NH4)2SO4, 4g / L; urea, 1g / L; KH2PO4, 1g / L; K2HPO4·3H2O, 1.3g / L; MOPS, 42g / L; CaCl2, 0.01g / L; FeSO4·7H2O, 0.01g / L; MnSO4·H2O, 0.01g / L; ZnSO4·7H2O, 0.001g / L; CuSO4, 0.0002g / L; NiCl·6H2O, 0.00002g / L; MgSO4·7H2O, 0.25g / L; protocatechuic acid, 0.03g / L; vitamin B1, 0.0001g / L; biotin, 0.0002g / L; glucose, 40g / L; H2SO4 to adjust pH Between 7.1-7.2.

[0016] The second aspect provides a protein that specifically effluxes L-threonine obtained by screening using the screening method of the first aspect, wherein the protein is selected from at least one of the following (A1) to (A4):

[0017] (A1) whose amino acid sequence is shown in any one of SEQ ID NO. 3, 5 or 7;

[0018] (A2) a protein having the same function as (A1) by replacing and / or deleting and / or adding one or more amino acid residues in the amino acid sequence shown in any one of SEQ ID NO. 3, 5 or 7;

[0019] (A3) a protein having 90% or more, preferably 95% or more, more preferably 96%, 97%, 98%, or 99% homology with the amino acid sequence defined in either (A1) or (A2), and having the same function as (A1);

[0020] (A4) a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of any of the proteins defined in (A1) to (A3);

[0021] The protein that specifically effluxes L-threonine is unable to efflux homoserine.

[0022] The third aspect provides a use of a specific L-threonine efflux protein in improving the L-threonine yield of a starting bacterium, wherein the L-threonine efflux protein is selected from at least one of (A1) to (A4):

[0023] (A1) whose amino acid sequence is shown in any one of SEQ ID NO. 3, 5 or 7;

[0024] (A2) a protein having the same function as (A1) by replacing and / or deleting and / or adding one or more amino acid residues in the amino acid sequence shown in any one of SEQ ID NO. 3, 5 or 7;

[0025] (A3) a protein having 90% or more, preferably 95% or more, more preferably 96%, 97%, 98%, or 99% homology with the amino acid sequence defined in either (A1) or (A2), and having the same function as (A1);

[0026] (A4) A fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of the protein defined in any one of (A1) to (A3).

[0027] Preferably, the microorganism is a microorganism of the genus Corynebacterium; further preferably, the microorganism of the genus Corynebacterium is Corynebacterium glutamicum.

[0028] In a specific embodiment of the present invention, the Corynebacterium glutamicum is Corynebacterium glutamicum ATCC13032, Corynebacterium glutamicum ATCC13869, Corynebacterium glutamicum ATCC 14067 or a derivative strain of any one of the above.

[0029] In the above-mentioned protein, the tag refers to a polypeptide or protein that is fused and expressed together with the target protein using DNA in vitro recombination technology to facilitate the expression, detection, tracing and / or purification of the target protein; the protein tag can be a Flag tag, a His tag, an MBP tag, an HA tag, a myc tag, a GST tag and / or a SUMO tag, etc.

[0030] In a fourth aspect, a recombinant strain with improved L-threonine production is provided, characterized in that the activity of the L-threonine efflux protein in the recombinant strain is enhanced relative to that of the starting strain, and the L-threonine efflux protein is selected from at least one of (A1) to (A4):

[0031] (A1) whose amino acid sequence is shown in any one of SEQ ID NO. 3, 5 or 7;

[0032] (A2) a protein having the same function as (A1) by replacing and / or deleting and / or adding one or more amino acid residues in the amino acid sequence shown in any one of SEQ ID NO. 3, 5 or 7;

[0033] (A3) a protein having 90% or more, preferably 95% or more, more preferably 96%, 97%, 98%, or 99% homology with the amino acid sequence defined in either (A1) or (A2), and having the same function as (A1);

[0034] (A4) A fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of the protein defined in any one of (A1) to (A3).

[0035] Preferably, the recombinant strain is a microorganism of the genus Corynebacterium. Further preferably, the microorganism of the genus Corynebacterium is Corynebacterium glutamicum.

[0036] In a specific embodiment of the present invention, the Corynebacterium glutamicum is Corynebacterium glutamicum ATCC13032, Corynebacterium glutamicum ATCC13869, Corynebacterium glutamicum ATCC 14067 or a derivative strain of any one of the above.

[0037] In the above-mentioned protein, the tag refers to a polypeptide or protein that is fused and expressed together with the target protein using DNA in vitro recombination technology to facilitate the expression, detection, tracing and / or purification of the target protein; the protein tag can be a Flag tag, a His tag, an MBP tag, an HA tag, a myc tag, a GST tag and / or a SUMO tag, etc.

[0038] In a fifth aspect, there is provided the use of the recombinant strain described in the fourth aspect in increasing the L-threonine production of the starting bacteria.

[0039] In a sixth aspect, a method for constructing the recombinant strain according to the fourth aspect is provided, the method comprising overexpressing an L-threonine efflux protein gene in a starting bacterium, wherein the L-threonine efflux protein is selected from at least one of (A1) to (A4):

[0040] (A1) whose amino acid sequence is shown in any one of SEQ ID NO. 3, 5 or 7;

[0041] (A2) a protein having the same function as (A1) by replacing and / or deleting and / or adding one or more amino acid residues in the amino acid sequence shown in any one of SEQ ID NO. 3, 5 or 7;

[0042] (A3) a protein having 90% or more, preferably 95% or more, more preferably 96%, 97%, 98%, or 99% homology with the amino acid sequence defined in either (A1) or (A2), and having the same function as (A1);

[0043] (A4) A fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of the protein defined in any one of (A1) to (A3).

[0044] Preferably, the strain is a microorganism of the genus Corynebacterium. Further preferably, the microorganism of the genus Corynebacterium is Corynebacterium glutamicum.

[0045] In a specific embodiment of the present invention, the Corynebacterium glutamicum is Corynebacterium glutamicum ATCC13032, Corynebacterium glutamicum ATCC13869, Corynebacterium glutamicum ATCC 14067 or a derivative strain of any one of the above.

[0046] In the above-mentioned protein, the tag refers to a polypeptide or protein that is fused and expressed together with the target protein using DNA in vitro recombination technology to facilitate the expression, detection, tracing and / or purification of the target protein; the protein tag can be a Flag tag, a His tag, an MBP tag, an HA tag, a myc tag, a GST tag and / or a SUMO tag, etc.

[0047] In a seventh aspect, a method for increasing the production of L-threonine in a microorganism is provided, the method comprising: enhancing the activity of an L-threonine efflux protein in a starting bacterium, wherein the L-threonine efflux protein is selected from at least one of (A1) to (A4):

[0048] (A1) whose amino acid sequence is shown in any one of SEQ ID NO. 3, 5 or 7;

[0049] (A2) a protein having the same function as (A1) by replacing and / or deleting and / or adding one or more amino acid residues in the amino acid sequence shown in any one of SEQ ID NO. 3, 5 or 7;

[0050] (A3) a protein having 90% or more, preferably 95% or more, more preferably 96%, 97%, 98%, or 99% homology with the amino acid sequence defined in either (A1) or (A2), and having the same function as (A1);

[0051] (A4) A fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of the protein defined in any one of (A1) to (A3).

[0052] Preferably, the microorganism is a microorganism of the genus Corynebacterium; further preferably, the microorganism of the genus Corynebacterium is Corynebacterium glutamicum.

[0053] In a specific embodiment of the present invention, the Corynebacterium glutamicum is Corynebacterium glutamicum ATCC13032, Corynebacterium glutamicum ATCC13869, Corynebacterium glutamicum ATCC 14067 or a derivative strain of any one of the above.

[0054] In the above-mentioned protein, the tag refers to a polypeptide or protein that is fused and expressed together with the target protein using DNA in vitro recombination technology to facilitate the expression, detection, tracing and / or purification of the target protein; the protein tag can be a Flag tag, a His tag, an MBP tag, an HA tag, a myc tag, a GST tag and / or a SUMO tag, etc.

[0055] In an eighth aspect, the present invention provides a method for producing L-threonine, the method comprising producing a target amino acid using the L-threonine producing strain of the fourth aspect, and optionally comprising a step of separating the L-threonine from the fermentation broth.

[0056] Beneficial effects of the present invention:

[0057] The present invention provides a method for rapidly and effectively identifying L-threonine efflux proteins on a large scale, through which L-threonine efflux proteins can be rapidly screened for genes on a whole genome scale. The method has the advantages of being simple, rapid, high throughput, and high hit rate, making the identification and mining of functional genes more efficient.

[0058] The present invention overexpresses 6 L-threonine efflux proteins in the screened Corynebacterium glutamicum, and finds that compared with the control strain, the intracellular L-threonine concentration of the 6 membrane protein overexpression strains at all time points is significantly lower than that of the control, while the extracellular L-threonine concentration is significantly higher than that of the control, indicating that the 6 membrane proteins screened can all expel L-threonine. Overexpression of Cgl2078, Cgl2344 and Cgl2656 identified by the present invention all leads to a decrease in homoserine production, indicating that these efflux proteins cannot expel homoserine and are more conducive to the production and application of L-threonine. BRIEF DESCRIPTION OF THE DRAWINGS

[0059] Figure 1 This is a diagram showing the preliminary screening results of the threonine efflux protein of the present invention;

[0060] Figure 2 The effects of overexpression of different threonine efflux proteins on intracellular and extracellular L-threonine concentrations; DETAILED DESCRIPTION

[0061] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.

[0062] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods. The experimental methods in the following examples without specifying specific conditions are usually carried out according to conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer.

[0063] Terms and Definitions

[0064] When used in conjunction with the term "comprising" in the claims and / or the specification, the word "a" or "an" can mean "one", but can also mean "one or more", "at least one" and "one or more than one".

[0065] As used in the claims and description, the words "comprising," "having," "including," or "containing" are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

[0066] Throughout this application, the term "about" indicates that a value includes the standard deviation of error for the device or method being employed to determine the value.

[0067] Although the disclosure supports a definition of the term "or" as only alternatives as well as "and / or," the term "or" in the claims means "and / or" unless explicitly stated as only alternatives or the alternatives are mutually exclusive.

[0068] The "starting strain" and "wild-type strain" in the present invention can be microorganisms that have not been artificially modified and can be found in nature. In addition, wild-type microorganisms also include derivative microorganisms that have undergone certain modifications and transformations. It should be noted that, for example, in the present invention, as long as the efflux protein of the present invention is not introduced into the strain or its expression level is enhanced, it can be considered as the starting strain.

[0069] The term "recombinant strain" of the present invention refers to a modified strain obtained by recombining using genetic engineering methods. The embodiments include but are not limited to increasing the copy number of protein coding genes, modifying the sequence of protein coding genes, introducing exogenous recombinant genes, etc.

[0070] The term "polynucleotide" in the present invention refers to a polymer composed of nucleotides. A polynucleotide can be in the form of a separate fragment or a component of a larger nucleotide sequence structure, which is derived from a nucleotide sequence separated at least once in quantity or concentration, and can be identified, manipulated, and recovered by standard molecular biology methods (e.g., using a cloning vector) and its component nucleotide sequences. When a nucleotide sequence is represented by a DNA sequence (i.e., A, T, G, C), this also includes an RNA sequence (i.e., A, U, G, C), in which "U" replaces "T". In other words, "polynucleotide" refers to a nucleotide polymer removed from other nucleotides (separate fragments or entire fragments), or can be a component or ingredient of a larger nucleotide structure, such as an expression vector or a polycistronic sequence. Polynucleotides include DNA, RNA, and cDNA sequences. "Recombinant polynucleotide" is one of the "polynucleotides".

[0071] The term "coding gene" in the present invention refers to a DNA molecule that can guide the synthesis of proteins through certain rules. The process of protein coding gene guiding protein synthesis generally includes a transcription process with double-stranded DNA as a template and a translation process with mRNA as a template. The coding gene contains a CDS sequence (Coding Sequence) that can guide the production of mRNA encoding protein. Exemplarily, the protein coding gene in the present invention is a gene encoding L-threonine efflux protein.

[0072] The terms "sequence homology" and "homology percentage" in the present invention refer to the percentage of nucleotides or amino acids that are identical (i.e., identical) between two or more polynucleotides or polypeptides. The sequence homology between two or more polynucleotides or polypeptides can be determined by the following method: the nucleotide or amino acid sequences of the polynucleotides or polypeptides are aligned and the number of positions containing the same nucleotide or amino acid residue in the aligned polynucleotides or polypeptides is scored, and compared with the number of positions containing different nucleotides or amino acid residues in the aligned polynucleotides or polypeptides. The polynucleotides may differ at one position, for example, by containing different nucleotides (i.e., substitutions or mutations) or missing nucleotides (i.e., nucleotide insertions or nucleotide deletions in one or two polynucleotides). The polypeptides may differ at one position, for example, by containing different amino acids (i.e., substitutions or mutations) or missing amino acids (i.e., amino acid insertions or amino acid deletions in one or two polypeptides). Sequence homology can be calculated by dividing the number of positions containing the same nucleotide or amino acid residue by the total number of amino acid residues in the polynucleotide or polypeptide. For example, percent homology can be calculated by dividing the number of positions containing the identical nucleotide or amino acid residue by the total number of nucleotides or amino acid residues in the polynucleotide or polypeptide and multiplying by 100.

[0073] In some embodiments, two or more sequences or subsequences have a "sequence homology" or "percent homology" of at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% nucleotides when compared and aligned for maximum correspondence using a sequence comparison algorithm or as measured by visual inspection. In certain embodiments, the sequences are substantially identical over the entire length of either or both of the compared biopolymers (e.g., polynucleotides).

[0074] As used in this disclosure, the term "expression" includes any step involved in RNA production and protein production including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

[0075] As used in the present disclosure, the term "vector" refers to a DNA construct containing a DNA sequence operably linked to an appropriate control sequence to express a target gene in a suitable host. "Recombinant expression vector" refers to a DNA structure used to express, for example, a polynucleotide encoding a desired polypeptide. A recombinant expression vector may include, for example, a collection of genetic elements that regulate gene expression, such as promoters and enhancers; ii) a structural or coding sequence that is transcribed into mRNA and translated into a protein; and iii) a transcription subunit that is suitable for transcription and translation initiation and termination sequences. The recombinant expression vector is constructed in any suitable manner. The nature of the vector is not important, and any vector may be used, including plasmids, viruses, phages, and transposons. Possible vectors for use in the present disclosure include, but are not limited to, chromosomal, non-chromosomal, and synthetic DNA sequences, such as bacterial plasmids, phage DNA, yeast plasmids, and vectors derived from a combination of plasmids and phage DNA, DNA from viruses such as vaccinia, adenovirus, fowlpox, baculovirus, SV40, and pseudorabies. In the present disclosure, "recombinant expression vector" and "recombinant vector" can be used interchangeably.

[0076] In some embodiments, "enhancement of protein activity" has a meaning well known to those skilled in the art, including enhancement of the expression level of protein-coding genes, enhancement of the transcription level of protein-coding genes, enhancement of protein activity, etc., including recombinant strains transformed by the following genetic engineering methods: introducing strong promoters and strong ribosome binding sites into the strains; introducing recombinant expression vectors of non-integrated proteins; introducing recombinant expression vectors of chromosomal-integrated proteins; changing the promoter, translation regulatory region or coding region codons of the coding gene to enhance its transcription or translation; changing the coding gene sequence to enhance its mRNA stability or stabilize the structure of the encoded protein; or any other method of enhancing its activity by modifying the gene coding region and its adjacent upstream and downstream regions.

[0077] The term "overexpression" as used herein has the meaning conventionally understood by those skilled in the art, and can be implemented by methods known in the art, including but not limited to: inserting a polynucleotide comprising a polynucleotide sequence encoding a protein into a chromosome, and / or cloning the polynucleotide into a vector and introducing it into a microorganism, and / or directly increasing the copy number of the polynucleotide on the chromosome, and / or modifying a promoter having a polynucleotide encoding a protein to enhance the transcription initiation rate, and / or modifying the transcription of a polynucleotide encoding a protein to enhance its activity, and / or modifying the translation regulatory sequence of a messenger RNA carrying the polynucleotide encoding the protein to enhance the translation intensity, and / or modifying the polynucleotide encoding the protein itself to enhance mRNA stability, protein stability, relieve protein feedback inhibition, etc., and can also include, without limitation, any known method for introducing protein activity.

[0078] " L-Threonine production strain " in the present invention means any type of strain that can be used to produce amino acid, and its strain source includes but is not limited to Escherichia (Escherichia), Erwinia (Erwinia), Serratia (Serratia), Providencia (Providencia), Enterobacteria (Enterobacteria), Salmonella (Salmonella), Streptomyces (Streptomyces), Pseudomonas (Pseudomonas), Brevibacterium (Brevibacterium) or Corynebacterium (Corynebacterium). In some embodiments, the amino acid production strain derives from Corynebacterium glutamicum. In some preferred embodiments, the amino acid production strain derives from Corynebacterium glutamicum ATCC13032, Corynebacterium glutamicum ATCC13869, Corynebacterium glutamicum ATCC 14067 or any of the above-mentioned derivative strains.

[0079] In some embodiments, the strain may be a strain expressing aspartate kinase LysC with de-feedback inhibition based on Corynebacterium glutamicum ATCC 13032. The prior art has reported that LysC with de-feedback inhibition, such as LysC T311I , LysC S301F , LysC L301K , LysC L301M , LysC FBR , LysC I293Y , LysC I293Q , LysC D294F , LysC T307GEtc. It may also be a strain obtained by introducing the G378E mutation in homoserine dehydrogenase Hom. In addition, the L-threonine producing strain may also be other types of strains having the ability to produce L-threonine.

[0080] In some embodiments, the L-threonine producing strain may also include but is not limited to one or more genes selected from the following being enhanced or overexpressed:

[0081] a. thrABC genes encoding the L-threonine operon;

[0082] b. hom gene encoding homoserine dehydrogenase that relieves feedback inhibition;

[0083] c. gap gene encoding glyceraldehyde-3-phosphate dehydrogenase;

[0084] d. pyc gene encoding pyruvate carboxylase;

[0085] e. mqo gene encoding malate:quinone oxidoreductase;

[0086] f. tkt gene encoding transketolase;

[0087] g. gnd gene encoding 6-phosphogluconate dehydrogenase;

[0088] h. thrE gene encoding L-threonine efflux protein;

[0089] i. The eno gene encoding enolase.

[0090] The term "transformation" of the present invention has the meaning generally understood by those skilled in the art, i.e., the process of introducing exogenous DNA into a strain. The method of transformation includes any method of introducing nucleic acid into a cell, including but not limited to electroporation, calcium phosphate precipitation, calcium chloride (CaCl2) precipitation, microinjection, polyethylene glycol (PEG) method, DEAE-dextran method, cationic liposome method and lithium acetate-DMSO method.

[0091] The strain of the present invention can be cultured according to conventional methods in the art, including but not limited to well plate culture, shake flask culture, batch culture, continuous culture and batch fed culture, and various culture conditions such as temperature, time and pH value of the culture medium can be appropriately adjusted according to actual conditions.

[0092] Example 1: Construction of a single gene overexpression plasmid for the whole genome of C. glutamicum ATCC13032

[0093] Based on the pEC-ccdB plasmid, a derivative of the pEC-XK99E plasmid (GenBank: AY219683.1), a single gene overexpression plasmid for the whole genome of C. glutamicum ATCC13032 was constructed. trc The promoter controls the expression of the gene. The plasmid pEC-ccdB is subjected to a single restriction enzyme digestion by BsaI endonuclease to obtain a linearized vector. According to the sequence information of the plasmid pEC-ccdB, homologous primers CglXXXX-F and CglXXXX-R (Table 1) containing the plasmid backbone portion are designed. According to the reported genome sequence of Corynebacterium glutamicum ATCC13032 (GenBank: BA000036.3), the coding gene fragment is amplified using the ATCC13032 genome as a template. After the linearized vector and target gene fragment were recovered, they were connected with the one-step recombination kit of Novozyme and transformed into E.coli Trans-T1 (Beijing Quanshijin Biotechnology), coated on LB solid medium containing 25μg / mL kanamycin, and cultured overnight at 37°C. The obtained transformants were verified by PCR using the universal primers PTRC99C-F and PBV220-R of the plasmid pEC-ccdB, and sent to a sequencing company for sequencing verification. The correct recombinant plasmid was named pEC-cglxxxx. At the same time, a control plasmid pEC-0 without cloning any gene sequence was constructed. Taking pEC-cgl0605 as an example, the plasmid sequence is shown in SEQ ID NO.1, and the overexpression plasmid sequence of other genes can be obtained by simply replacing the coding sequence of different genes. The whole genome of C. glutamicum ATCC13032 has nearly 400 predicted membrane transport proteins. The amino acid sequence of Cgl0605 directly involved in the present invention is shown as SEQ ID NO: 2; the amino acid sequence of Cgl2078 is shown as SEQ ID NO: 3; the amino acid sequence of Cgl2286 is shown as SEQ ID NO: 4; the amino acid sequence of Cgl2344 is shown as SEQ ID NO: 5; the amino acid sequence of Cgl2622 is shown as SEQ ID NO: 6; and the amino acid sequence of Cgl2656 is shown as SEQ ID NO: 7.

[0094] Table 1

[0095]

[0096]

[0097] Example 2. Construction of an overexpression library of membrane transporter proteins from C. glutamicum ATCC13032

[0098] According to the method reported in conventional literature, C. glutamicum ATCC 13032 competent cells were prepared, and nearly 400 overexpression plasmids and pEC-0 control plasmids successfully constructed in Example 1 were respectively transferred into C. glutamicum ATCC13032 competent cells, 1 mL of TSB medium preheated at 46°C was added, incubated at 46°C for 6 min, incubated at 30°C for 2 h, coated on TSB solid medium containing 5 μg / mL chloramphenicol, and cultured at 30°C for 1 day to obtain transformants. The components of TSB liquid medium are (g / L): glucose, 5g / L; yeast powder, 5g / L; soy peptone, 9g / L; urea, 3g / L; succinic acid, 0.5g / L; K2HPO4·3H2O, 1g / L; MgSO4·7H2O, 0.1g / L; biotin, 0.01mg / L; vitamin B1, 0.1mg / L; MOPS, 20g / L. TSB solid medium is supplemented with 15g / L agar powder. The transformants were verified by PCR and sequencing using primers pTRC99C-F and pBV220-R, and the correct recombinant strain was named ATCC13032 (pEC-cglxxx).

[0099] Example 3. Initial screening of L-threonine efflux proteins

[0100] Since adding oligopeptides in the culture medium can cause high concentrations of amino acids to accumulate in bacteria such as Corynebacterium glutamicum, affecting the growth of cells, and enhancing the expression of amino acid efflux proteins can accelerate the transport of excess amino acids to the extracellular space, which is conducive to the growth of cells in oligopeptide environments, this phenomenon can be used to screen L-threonine efflux proteins. Since the overexpression of membrane transporters also has an impact on cell growth, the present invention screens possible L-threonine efflux proteins by comparing the impact of membrane transporters on cell growth under the condition of having / without Thr-Thr dipeptide.

[0101] The C. glutamicum ATCC13032 membrane transporter overexpression library constructed in Example 2, totaling 388 strains, was screened under threonine dipeptide stress. The seed culture and screening process were both performed using a MicroScreen fully automatic microbial growth curve analyzer (Jie Ling Company, Tianjin), and the OD 600. Seed culture was as follows: the overexpression strain of the C. glutamicum ATCC13032 membrane transporter overexpression library and the control strain C. glutamicum ATCC13032 (pEC-0) were inoculated into TSB liquid medium containing 25 μg / mL kanamycin. The culture system was a 48-well plate with 400 μL of liquid, 800 rpm, and cultured at 30°C for 8 h. The cultured seed solution was inoculated into TSB liquid medium containing 0.04 mM IPTG and 25 μg / mL kanamycin. The culture system was a 48-well plate with 400 μL of liquid, and cultured at 30°C for 8 h; it was inoculated again into CGXII medium containing 6 mM Thr-Thr dipeptide and no Thr-Thr dipeptide. The culture system was a 48-well plate with 400 μL of liquid. The culture medium contained 0.4 mM IPTG and 25 μg / mL kanamycin. The culture was 800 rpm and cultured at 30°C for 18 h. The cell growth OD was measured every 1 h. 600 , comprehensively characterize the effect of membrane transporter overexpression on cell growth in the presence / absence of Thr-Thr dipeptide. The composition of CGXII medium is (g / L): (NH4)2SO4, 20g / L; urea, 5g / L; KH2PO4, 1g / L; K2HPO4·3H2O, 1.3g / L; MOPS, 42g / L; CaCl2, 0.01g / L; FeSO4·7H2O, 0.01g / L; MnSO4·H2O, 0.01g / L; ZnSO4·7H2O, 0.001g / L; CuSO4, 0.0002g / L; NiCl·6H2O, 0.00002g / L; MgSO4·7H2O, 0.25g / L; protocatechuic acid, 0.03g / L; vitamin B1, 0.0001g / L; biotin, 0.0002g / L; glucose, 40g / L; H2SO4 to adjust pH 7.1-7.2. The medium containing 6 mM Thr-Thr dipeptide is composed of CGXII medium supplemented with Thr-Thr dipeptide at a final concentration of 6 mM.

[0102] The initial screening criteria for L-threonine efflux proteins are as follows: First, calculate the OD of the overexpression strain at each 1-h interval under the condition of adding dipeptide during the exponential growth period for 5 consecutive hours. 600 OD of control strain 600 Ratio and the average of the ratios at these five time points; OD of the overexpression strain at each 1h interval under the condition without adding dipeptide 600 OD of control strain 600The ratio and the average of the ratios at these five time points were calculated; the difference between the average of the five ratios under the condition of adding dipeptide and the average of the five ratios under the condition of not adding dipeptide was calculated. If the difference is ≥40%, it indicates that the overexpression of the membrane transporter is specifically conducive to the growth under Thr-Thr dipeptide conditions and is a possible L-threonine efflux protein. The results are shown in Figure 1 As shown in Table 2, the triangles represent the OD of the overexpression strain under the condition of adding dipeptide in the culture medium. 600 OD of control strain 600 The average value of the ratio, the circle represents the OD of the overexpression strain in the medium without adding dipeptide 600 OD of control strain 600 The average value of the ratio, a total of 33 membrane protein genes met the initial screening criteria for L-threonine efflux proteins, including the following genes cgl0181, cgl0322, cgl0533, cgl0605, cgl0810, cgl0850, cgl0886, cgl0933, cgl0968, cgl1065, cgl1071, cgl1270, cgl1360, cgl1933, cgl2078, cgl l2222, cgl2286, cgl2318, cgl2344, cgl2492, cgl2553, cgl2611, cgl2622, cgl2656, cgl2744, cgl2783, cgl2823, cgl2843, cgl2929, cgl3006, cgl3036, cgl3058, cgl3082, the difference in the ratio averages is between 45% and 158%.

[0103] Table 2 Preliminary screening of L-threonine efflux proteins

[0104]

[0105]

[0106] Example 4. Multiple screening of L-threonine efflux proteins

[0107] The 33 membrane proteins obtained in the primary screening in Example 3 were rescreened by detecting the concentration of L-threonine using a liquid chromatograph (Tsushima, Japan) and cultured using a MicroScreen fully automatic microbial growth curve analyzer. The overexpression strains of 33 genes obtained in the initial screening and the control strain C. glutamicum ATCC13032 (pEC-0) were inoculated into TSB liquid culture medium containing 25 μg / mL kanamycin. The culture system was a 48-well plate, filled with 400 μL of liquid, 800 rpm, and cultured at 30°C for 8 hours. The bacterial liquid was inoculated into TSB liquid culture medium containing 0.04 mM IPTG and 25 μg / mL kanamycin. The culture system was a 48-well plate, filled with 400 μL of liquid, 800 rpm, and cultured at 30°C for 8 hours. The 48-well plate was centrifuged and the supernatant was discarded. 400 μL of CGXII fine-tuning culture medium with a concentration of 6 mM thr-Thr dipeptide was added and mixed by pipetting. The culture medium contained 0.4 mM IPTG and 25 μg / mL kanamycin. The culture was carried out at 800 rpm and 30°C for 1 hour before sampling. CGXII fine-tuning medium is compared to CGXII medium, in which (NH4)2SO4 is changed to 4g / L, urea is changed to 1g / L, and the other components remain unchanged. The evaluation standard for rescreening is to calculate the unit OD 600 L-threonine efflux of the strain is L-threonine concentration / initial OD 600 , the concentration of L-threonine was more than 20% higher than that of the control. The results are shown in Table 3. Among the 33 membrane proteins obtained in the initial screening, only 6 genes, cgl0605, cgl2078, cgl2286, cgl2344, cgl2622 and cgl2656, met the rescreening criteria after rescreening, with an increase of 27%-60%.

[0108] Table 3. Multiple screening of L-threonine efflux proteins

[0109]

[0110] Example 5. Functional verification of L-threonine efflux protein

[0111] The strains ATCC13032 (pEC-cgl0605), ATCC13032 (pEC-cgl2078), ATCC13032 (pEC-cgl2286), ATCC13032 (pEC-cgl2344), ATCC13032 (pEC-cgl2622), ATCC13032 (pEC-cgl2656) and the control strain ATCC13032 (pEC-0) were inoculated into TSB liquid medium containing 25 μg / mL kanamycin, and the culture system was a 100 mL Erlenmeyer flask with 10 mL of liquid, and a shaking shaker (Zhichu Instrument Co., Ltd., Shanghai) was used at 220 rpm and 30°C for 8 h. The seed liquid was inoculated into TSB liquid medium containing 0.04 mM IPTG and 25 μg / mL kanamycin, and the culture system was a 250 mL Erlenmeyer flask with 30 mL of liquid, and the culture was carried out at 220 rpm and 30°C for 8 h. The bacterial suspension was inoculated into a 6 mM Thr-Thr dipeptide CGXII fine-tuning medium containing 0.4 mM IPTG and 25 μg / mL kanamycin. 600 The value is 10, and the culture system is a 100mL Erlenmeyer flask, filled with 10mL of liquid, and cultured at 220rpm and 30℃ for 2h. During the culture process, samples were taken every 20min, with a sample volume of 400μL, added to the upper layer of silicone oil with a density of 1.05, and centrifuged at 12000rpm for 5min. After the centrifugation, the supernatant was taken out and the bacterial mud was cut into 400μL of sulfosalicylic acid. The bacterial mud was blown and mixed, and then boiled in a water bath for 45min, and centrifuged at 12000rpm for 5min to take the supernatant. The sampling time points were 0min, 20min, 40min, 60min and 80min. The concentrations of intracellular and extracellular L-threonine were detected by liquid chromatography. When calculating the intracellular concentration, 1OD 600 Corresponding to 0.3 mg / L dry cell weight (DCW), the cell volume is converted to 1.7 μL / mgDCW. Figure 2 As shown in Table 4, compared with the control strain, the intracellular L-threonine concentration of the six membrane protein overexpression strains was significantly lower than that of the control at all time points, while the extracellular L-threonine concentration was significantly higher than that of the control, indicating that the six membrane proteins screened can all exclude L-threonine, among which Cgl0605 (Microb Cell Fact. 2020 May 29; 19 (1): 115.) and Cgl2622 (J Bacteriol. 2001 Sep; 183 (18): 5317-24.) are L-threonine efflux proteins that have been reported in the literature, further indicating that the high-throughput screening method for L-threonine efflux proteins of the present invention has a very high screening efficiency, and is more capable of simultaneously and systematically identifying multiple L-threonine efflux proteins than previous methods.

[0112] Table 4 Intracellular and extracellular L-threonine concentrations and changes at 80 min after overexpression of different efflux proteins

[0113] strain Intracellular concentration (mM) Decline Extracellular concentration (mM) Increase ATCC13032(pEC-0) 197.21±2.25 - 4.99±0.07 - ATCC13032(pEC-cgl0605) 30.79±5.43 84% 6.91±0.12 37% ATCC13032 (pEC-cgl2078) 95.35±0.94 52% 6.12±0.17 23% ATCC13032 (pEC-cgl2286) 142.04±7.73 28% 5.61±0.08 14% ATCC13032 (pEC-cgl2344) 122.32±7.60 38% 5.49±0.05 10% ATCC13032 (pEC-cgl2622) 18.27±2.03 91% 6.84±0.03 38% ATCC13032 (pEC-cgl2656) 101.29±6.72 49% 5.71±0.11 12%

[0114] Example 6. Application of L-threonine efflux protein

[0115] First, a L-threonine producing strain of Corynebacterium glutamicum SSBL378 was constructed. The specific construction was as follows: First, the aspartate kinase gene lysC of Corynebacterium glutamicum ATCC13032 was introduced with a T311I (base mutation from ACC to ATC) amino acid mutation, and the homoserine dehydrogenase gene hom was introduced with a G378E (base mutation from GGG to GAG) amino acid mutation, to obtain ATCC13032hom G378E lysC T311I Secondly, a constitutive promoter-based overexpression strain was constructed on the pXMJ19 plasmid (GenBank: AJ133195.1). G378E and homoserine kinase thrB gene plasmid, pXMJ19 plasmid was amplified using primers pXMJ19-1 (sequence: GTCGACTCTAGAGGATCCCCG) and pXMJ19-2 (sequence: AGGGCAATCAGCTGTTGCC); pXMJ19 plasmid was amplified using primers HT-1 (sequence: GGGCAACAGCTGATTGCCCT GCTCCCTCCGCCCCAGGCCCATGACAGGTGGGGCTAACCTCCCCTATGAGTTTTTACAATGAGACAATTGCCAAAGGATCACGATGACCTCAGCATCTGCCCCA); CTAAGGTTGGTTAACTTCAACCTTG) as primers (the constitutive promoter was directly added through primers, sequence: GCTCCCTCCGCCCCAGGCCCATGACAGGTGGGGGCTAACCTCCCCTATGAGTTTTTACAATGAGACAATTGCCAAAGGATCACG), and the genome of the previously introduced genomic mutant bacteria was used as a template to amplify hom G378E thrB expression cassette; the above two fragments were cloned and connected by Novozymes' one-step recombination kit to obtain pXMJ19-hom G378E Finally, pXMJ19-hom G378E thrB plasmid was introduced into ATCC13032hom G378E lysC T311I strain, and the SSBL378 strain can be obtained.

[0116] The pEC-cgl0605, pEC-cgl2078, pEC-cgl2286, pEC-cgl2344, pEC-cgl2622, pEC-cgl2656 and control pEC-0 plasmids constructed in Example 1 were respectively transformed into the L-threonine producing bacteria SSBL378 by electroporation to obtain SSBL378 (pEC-cgl0605), SSBL378 (pEC-cgl2078), SSBL378 (pEC-cgl2286), SSBL378 (pEC-cgl2344), SSBL378 (pEC-cgl2622), SSBL378 (pEC-cgl2656) and SSBL378 (pEC-0). The above overexpression strains and the control strain SSBL378 (pEC-0) were inoculated into TSB liquid medium containing 25 μg / mL kanamycin for seed culture. The culture system was 800 μL of liquid in a 24-well plate and cultured for about 8 h using a high-throughput shaker (Zhichu Instrument Co., Ltd., Shanghai) at 800 rpm and 30°C. The seed solution was heated at an initial OD 600 0.06 were transferred to the fermentation medium, and the fermentation medium was supplemented with 0.4mM IPTG, 15μg / mL kanamycin and 5μg / mL chloramphenicol. The culture system was a 24-well plate with 1mL of liquid in each well, 800rpm, 30℃ fermentation culture, and three parallels for each strain. The components of L-threonine fermentation medium are (g / L): glucose, 80g / L; yeast powder, 1g / L; soy peptone, 1g / L; NaCl, 1g / L; ammonium sulfate, 1g / L; urea, 8g / L; K2HPO4·3H2O, 1g / L; MgSO4·7H2O, 0.45g / L; FeSO4·7H2O, 0.05g / L; biotin, 0.4mg / L; VB1, 0.1mg / L; MOPS, 40g / L; Na2SO4, 85g / L; ammonia water was used to adjust the initial pH to 7.2. The OD was detected by an enzyme marker 600 The production of L-threonine and homoserine was detected by liquid chromatography, and the fermentation was terminated after 20 hours.

[0117] The results are shown in Table 5. Compared with the control strain, the overexpression of multiple efflux proteins can increase the L-threonine production, among which Cgl0605 increases by 36%, Cgl2078 increases by 42%, Cgl2344 increases by 51%, Cgl2622 increases by 112%, and Cgl2656 increases by 119%. However, Cgl2286 does not increase the L-threonine production due to the effect on cell growth. It is known that Cgl2622 (J Bacteriol. 2001 Sep; 183 (18): 5317-24.) and multiple L-threonine efflux proteins of Escherichia coli can also efflux homoserine, which is a precursor of L-threonine synthesis, which is not conducive to the production of L-threonine. Cgl2344 (GenBank: BAB99737.1) and Cgl2656 (GenBank: BAC00050.1) are also annotated as L-threonine / homoserine efflux proteins in the NCBI database. The results showed that the overexpression of the known L-threonine efflux proteins Cgl0605 and Cgl2622 led to an increase in homoserine production by 352% and 242%, respectively, indicating that they can indeed efflux homoserine; while the overexpression of the newly identified Cgl2078, Cgl2286, Cgl2344 and Cgl2656 in the present invention all led to a decrease in homoserine production, indicating that these efflux proteins cannot efflux homoserine. In summary, the L-threonine efflux proteins Cgl2078, Cgl2344 and Cgl2656 identified in the present invention are more conducive to the production and application of L-threonine.

[0118] Table 5 Effects of different L-threonine efflux proteins on L-threonine production

[0119]

Claims

1. A method for screening microbial L-threonine efflux proteins, characterized in that: The following steps are involved: 1) Construct a membrane transporter gene overexpression library based on the whole genome of microorganisms, and at the same time construct a control plasmid strain without any gene sequence cloned in the middle; 2) Compare the effects of overexpressing membrane transporters on cell growth under the conditions of culture with or without Thr-Thr dipeptide, and conduct preliminary screening of L-threonine efflux proteins; 3) Cultivating the membrane transporter overexpressing strain obtained in the initial screening of step 2) under Thr-Thr dipeptide culture conditions, detecting L-threonine efflux by liquid chromatography, and performing rescreening by comparing with the control plasmid strain.

2. The screening method according to claim 1, characterized in that The microorganism is a microorganism of the genus Corynebacterium; further preferably, the microorganism of the genus Corynebacterium is Corynebacterium glutamicum.

3. The screening method according to claim 2, characterized in that The step 2) specifically comprises transferring the seed solution of the microbial full genome membrane transporter gene overexpression strain and the control plasmid strain constructed in step 1) into a culture medium containing a final concentration of 6 mM Thr-Thr dipeptide and a culture medium without Thr-Thr dipeptide, respectively, culturing the culture medium using a MicroScreen fully automatic microbial growth curve analyzer, and automatically measuring the OD 600 The cell growth OD was measured every 1 h. 600 Calculate the OD of the overexpression strain at every 1-hour interval under the culture condition of adding Thr-Thr dipeptide during the exponential growth period for 5 consecutive hours. 600 OD of the control plasmid strain 600 The ratio and the average of the ratios at these five time points; the OD of the overexpression strain at each 1h interval under the culture condition without adding dipeptide 600 OD of the control plasmid strain 600 The ratio and the average of the ratios at these five time points are calculated; the difference between the average of the five ratios under the culture condition with the addition of dipeptide and the average of the five ratios under the culture condition without the addition of dipeptide is calculated. If the difference is ≥40%, it indicates that the overexpression of the membrane transporter is specifically conducive to the growth under the Thr-Thr dipeptide culture condition and is a possible L-threonine efflux protein; Further preferably, in step 2), the culture system is a 48-well plate, containing 400 μL of liquid, the culture medium is a CGXII liquid culture medium containing 0.04 mM IPTG and 25 μg / mL kanamycin, and the culture is carried out at 30°C and 800 rpm for 18 h. The components of the CGXII liquid culture medium are (g / L): (NH4)2SO4, 20 g / L; Uera, 5 g / L; KH2PO4, 1 g / L; K2HPO4·3H2O, 1.3 g / L; MOPS, 42 g / L; CaCl 2, 0.01g / L; FeSO4·7H2O, 0.01g / L; MnSO4·H2O, 0.01g / L; ZnSO4·7H2O, 0.001g / L; CuSO4, 0.0002g / L; NiCl·6H2O, 0.00002g / L; MgSO4·7H2O, 0.25g / L; Protocatechuic acid, 0.03g / L; VB1, 0.0001g / L; Biotin, 0.0002g / L; Glucose, 40g / L; H2SO4 was used to adjust the pH between 7.1-7.

2.

4. The screening method according to claim 3, characterized in that The step 3) specifically comprises rescreening the strains overexpressing the membrane transporter protein obtained by the initial screening in step 2) and the strains containing the control plasmid by detecting the concentration of L-threonine by liquid chromatography; culturing and measuring the OD using a MicroScreen fully automatic microbial growth curve analyzer 600 In the medium containing Thr-Thr dipeptide, the samples were cultured at 30℃ for 1 hour and then the rescreening evaluation standard was calculated in units of OD 600 L-threonine efflux of the strain is L-threonine concentration / initial OD 600 (g / L / OD 600 ), the L-threonine efflux rate was more than 20% higher than that of the control; Further preferably, in step 3), the culture system is a 48-well plate, filled with 400 μL of liquid, 800 rpm, and cultured at 30°C for 8 hours, then the bacterial liquid is inoculated into TSB liquid culture medium containing 0.04 mM IPTG and 25 μg / mL kanamycin. The culture system is a 48-well plate, filled with 400 μL of liquid, 800 rpm, and cultured at 30°C for 8 hours. The 48-well plate is centrifuged and the supernatant is discarded. 400 μL of CGXII fine-tuning culture medium with a concentration of 6 mM Thr-Thr dipeptide is added and mixed by pipetting. The culture medium contains 0.4 mM IPTG and 25 μg / mL kanamycin. After culturing at 800 rpm and 30°C for 1 hour, a sample is taken to detect the OD 600 The components of the CGXII liquid culture medium are (g / L): (NH4)2SO4, 20g / L; Uera, 5g / L; KH2PO4, 1g / L; K2HPO4·3H2O, 1.3g / L; MOPS, 42g / L; CaCl2, 0.01g / L; FeSO4·7H2O, 0.01g / L; MnSO4·H2O, 0.01g / L; ZnSO4·7H2O, 0.001g / L; CuSO4, 0.0002g / L; NiCl·6H2O, 0.00002g / L; MgSO4·7H2O, 0.25g / L; protocatechuic acid, 0.03g / L; VB1, 0.0001g / L; biotin, 0.0002g / L; glucose, 40g / L; H2SO4 to adjust pH Between 7.1-7.

2.

5. The protein that specifically effluxes L-threonine obtained by the screening method according to claim 1, characterized in that: The protein is selected from any one of (A1) to (A4): (A1) whose amino acid sequence is shown in any one of SEQ ID NO. 3, 5 or 7; (A2) a protein having the same function as (A1) by replacing and / or deleting and / or adding one or more amino acid residues in the amino acid sequence shown in any one of SEQ ID NO. 3, 5 or 7; (A3) a protein having 90% or more, preferably 95% or more, more preferably 96%, 97%, 98%, or 99% homology with the amino acid sequence defined in either (A1) or (A2), and having the same function as (A1); (A4) a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of any of the proteins defined in (A1) to (A3); The protein is unable to efflux homoserine.

6. Application of a specific L-threonine efflux protein in increasing the L-threonine yield of starting bacteria, characterized in that: The L-threonine efflux protein is selected from any one of (A1) to (A4): (A1) whose amino acid sequence is shown in any one of SEQ ID NO. 3, 5 or 7; (A2) a protein having the same function as (A1) by replacing and / or deleting and / or adding one or more amino acid residues in the amino acid sequence shown in any one of SEQ ID NO. 3, 5 or 7; (A3) a protein having a homology of 90% or more, preferably 95% or more, more preferably 96%, 97%, 98%, or 99% with the amino acid sequence defined in any one of (A1) or (A2), and having the same function as (A1); (A4) a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of any one of the proteins defined in (A1) to (A3); Preferably, the microorganism is a microorganism of the genus Corynebacterium; further preferably, the microorganism of the genus Corynebacterium is Corynebacterium glutamicum; In a specific embodiment of the present invention, the Corynebacterium glutamicum is Corynebacterium glutamicum ATCC13032, Corynebacterium glutamicum ATCC13869, Corynebacterium glutamicum ATCC 14067 or a derivative strain of any one of the above; In the above-mentioned protein, the tag refers to a polypeptide or protein that is fused and expressed together with the target protein using DNA in vitro recombination technology to facilitate the expression, detection, tracing and / or purification of the target protein; the protein tag can be a Flag tag, a His tag, an MBP tag, an HA tag, a myc tag, a GST tag and / or a SUMO tag, etc.

7. A recombinant strain with improved L-threonine production, characterized in that: The activity of the L-threonine efflux protein in the recombinant strain is enhanced relative to that of the starting strain, and the L-threonine efflux protein is selected from any one of (A1) to (A4): (A1) whose amino acid sequence is shown in any one of SEQ ID NO. 3, 5 or 7; (A2) a protein having the same function as (A1) by replacing and / or deleting and / or adding one or more amino acid residues in the amino acid sequence shown in any one of SEQ ID NO. 3, 5 or 7; (A3) a protein having a homology of 90% or more, preferably 95% or more, more preferably 96%, 97%, 98%, or 99% with the amino acid sequence defined in any one of (A1) or (A2), and having the same function as (A1); (A4) a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of any one of the proteins defined in (A1) to (A3); Preferably, the recombinant strain is a microorganism of the genus Corynebacterium. Further preferably, the microorganism of the genus Corynebacterium is Corynebacterium glutamicum; In a specific embodiment of the present invention, the Corynebacterium glutamicum is Corynebacterium glutamicum ATCC13032, Corynebacterium glutamicum ATCC13869, Corynebacterium glutamicum ATCC 14067 or a derivative strain of any one of the above; In the above-mentioned protein, the tag refers to a polypeptide or protein that is fused and expressed together with the target protein using DNA in vitro recombination technology to facilitate the expression, detection, tracing and / or purification of the target protein; the protein tag can be a Flag tag, a His tag, an MBP tag, an HA tag, a myc tag, a GST tag and / or a SUMO tag, etc.

8. Use of the recombinant strain according to claim 7 in increasing the L-threonine production of starting bacteria.

9. A method for increasing the production of L-threonine from microorganisms, characterized in that: The method comprises: enhancing the activity of L-threonine efflux protein in the starting bacteria, wherein the L-threonine efflux protein is selected from any one of (A1) to (A4): (A1) whose amino acid sequence is shown in any one of SEQ ID NO. 3, 5 or 7; (A2) a protein having the same function as (A1) by replacing and / or deleting and / or adding one or more amino acid residues in the amino acid sequence shown in any one of SEQ ID NO. 3, 5 or 7; (A3) a protein having a homology of 90% or more, preferably 95% or more, more preferably 96%, 97%, 98%, or 99% with the amino acid sequence defined in any one of (A1) or (A2), and having the same function as (A1); (A4) a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of any one of the proteins defined in (A1) to (A3); Preferably, the microorganism is a microorganism of the genus Corynebacterium; further preferably, the microorganism of the genus Corynebacterium is Corynebacterium glutamicum; In a specific embodiment of the present invention, the Corynebacterium glutamicum is Corynebacterium glutamicum ATCC13032, Corynebacterium glutamicum ATCC13869, Corynebacterium glutamicum ATCC 14067 or a derivative strain of any one of the above; In the above-mentioned protein, the tag refers to a polypeptide or protein that is fused and expressed together with the target protein using DNA in vitro recombination technology to facilitate the expression, detection, tracing and / or purification of the target protein; the protein tag can be a Flag tag, a His tag, an MBP tag, an HA tag, a myc tag, a GST tag and / or a SUMO tag, etc.

10. A method for producing L-threonine, characterized in that: The method comprises producing a target amino acid using the recombinant strain with improved L-threonine production according to claim 7, and optionally comprises a step of separating the L-threonine from the fermentation broth.

Citation Information

Cited By

  • Recombinant bacterium for producing gamma-aminobutyric acid as well as construction method and application of recombinant bacterium

    CN121801785A